G protein-coupled receptors: bridging the gap from the extracellular signals to the Hippo pathway.
暂无分享,去创建一个
[1] G. Bonamy,et al. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. , 2012, Chemistry & biology.
[2] K. Guan,et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. , 2011, Genes & development.
[3] O. Kirak,et al. Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation , 2011, Cell.
[4] David M. Thomas,et al. The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.
[5] R. Müller,et al. NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway , 2011, The Journal of cell biology.
[6] Zhengyu Zha,et al. The N-terminal Phosphodegron Targets TAZ/WWTR1 Protein for SCFβ-TrCP-dependent Degradation in Response to Phosphatidylinositol 3-Kinase Inhibition* , 2012, The Journal of Biological Chemistry.
[7] K. Guan,et al. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). , 2010, Genes & development.
[8] K. Guan,et al. The Hippo pathway: regulators and regulations. , 2013, Genes & development.
[9] Gary D Bader,et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. , 2010, The Biochemical journal.
[10] G. Longmore,et al. Ajuba LIM Proteins Are Negative Regulators of the Hippo Signaling Pathway , 2010, Current Biology.
[11] J. Stockman. Mutations in GNA11 in Uveal Melanoma , 2012 .
[12] Zhengyu Zha,et al. The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase* , 2010, The Journal of Biological Chemistry.
[13] Q. Zeng,et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. , 2008, Cancer research.
[14] C. Wells,et al. LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap , 2013, Oncogene.
[15] Kun-Liang Guan,et al. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. , 2013, Genes & development.
[16] R. Jaenisch,et al. YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells , 2007, Current Biology.
[17] S. Seshagiri,et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer , 2013, Nature Reviews Cancer.
[18] Zhengyu Zha,et al. TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway , 2008, Molecular and Cellular Biology.
[19] Jun O. Liu,et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.
[20] H. Cai,et al. The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells , 2013, Cell Communication and Signaling.
[21] Eun Jin Seo,et al. TAZ Mediates Lysophosphatidic Acid-Induced Migration and Proliferation of Epithelial Ovarian Cancer Cells , 2013, Cellular Physiology and Biochemistry.
[22] Yiqiang Zhao,et al. Phosphorylation of Angiomotin by Lats1/2 Kinases Inhibits F-actin Binding, Cell Migration, and Angiogenesis* , 2013, The Journal of Biological Chemistry.
[23] M. Wigler,et al. Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.
[24] Bin Zhao,et al. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal , 2011, Nature Cell Biology.
[25] Jiandie D. Lin,et al. TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.
[26] A. Stemmer-Rachamimov,et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. , 2011, Cancer cell.
[27] G. Barsh,et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi , 2010 .
[28] V. Sah,et al. The role of Rho in G protein-coupled receptor signal transduction. , 2000, Annual review of pharmacology and toxicology.
[29] Sirio Dupont. Role of YAP/TAZ in mechanotransduction , 2011 .
[30] D. Pan,et al. The hippo signaling pathway in development and cancer. , 2010, Developmental cell.
[31] M. Giovannini,et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. , 2010, Developmental cell.
[32] G. Feldmann,et al. Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.
[33] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[34] Li Li,et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.
[35] Zhengyu Zha,et al. TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition* , 2009, Journal of Biological Chemistry.
[36] Junjie Chen,et al. PTPN14 is required for the density-dependent control of YAP1. , 2012, Genes & development.
[37] C. Wells,et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases , 2013, Proceedings of the National Academy of Sciences.
[38] A. Rosato,et al. Metabolic control of YAP and TAZ by the mevalonate pathway , 2014, Nature Cell Biology.
[39] K. Guan,et al. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). , 2012, Genes & development.
[40] M. Goppelt‐Struebe,et al. Rho‐dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins) , 2001, British journal of pharmacology.
[41] M. Sudol,et al. Structures of YAP protein domains reveal promising targets for development of new cancer drugs. , 2012, Seminars in cell & developmental biology.
[42] S. Bicciato,et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.
[43] Y. Hata,et al. A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. , 2011, Journal of biochemistry.
[44] H. Ji,et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.
[45] J. Gutkind,et al. G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.
[46] Stefan Offermanns,et al. Mammalian G proteins and their cell type specific functions. , 2005, Physiological reviews.
[47] E. Montgomery,et al. Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.
[48] Junjie Chen,et al. Angiomotin-like Proteins Associate with and Negatively Regulate YAP1* , 2010, The Journal of Biological Chemistry.
[49] M. Ji,et al. KIBRA Regulates Hippo Signaling Activity via Interactions with Large Tumor Suppressor Kinases* , 2011, The Journal of Biological Chemistry.
[50] Y. Cho‐Chung. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. , 1990, Cancer research.
[51] Jindan Yu,et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. , 2012, Genes & development.
[52] Xiang-Dong Fu,et al. Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling , 2012, Cell.
[53] Kevin J. Cheung,et al. Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP* , 2008, Journal of Biological Chemistry.
[54] D. Faratian,et al. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals , 2013, Oncogene.
[55] G. Merlino,et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. , 2014, Cancer cell.
[56] Kang Zhang,et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. , 2014, Cancer cell.
[57] J. George,et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene , 2011, Oncogene.
[58] M. Hollenberg,et al. Thrombin‐mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase‐activated receptors 1 and 4 , 2007, Journal of cellular physiology.
[59] Li Li,et al. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. , 2010, Genes & development.
[60] H. Saya,et al. cAMP/PKA signalling reinforces the LATS–YAP pathway to fully suppress YAP in response to actin cytoskeletal changes , 2013, The EMBO journal.
[61] K. Harvey,et al. Upstream Regulation of the Hippo Size Control Pathway , 2010, Current Biology.
[62] K. Song,et al. Correlation of expression of phosphorylated and non-phosphorylated Yes-associated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population. , 2012, Anticancer research.
[63] C. Der,et al. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors , 2005, Nature Reviews Molecular Cell Biology.